Date

Wednesday, April 5th 2023 (17:00 - 18:00)

Language

English

Organised by

IQVIA Biotech

Categories

Tags

Join us for this webinar where we’ll look beyond the specific changes laid out in the Inflation Reduction Act (IRA) of 2022 and explore the second and third order effects and how they’ll play out over the next decade. Our IQVIA industry experts, Luke Greenwalt and Mason Tenaglia, will discuss how emerging biopharma companies (EBPs) can navigate through these changes to optimize their product performance.

Key takeaways:

  • How EBPs can best prepare for the changes and risks resulting from the IRA as they play out over the next decade

  • How to gauge the impact of different actions (and inactions) on a portfolio, short and long term

  • The potential impact for EBP companies related to market access, organizational strategy, gross-to-net economics, and financial strategy

Speakers:

  • Luke Greenwalt

    Vice President and Lead, IQVIA Market Access Center of Excellence

  • Mason Tenaglia

    Vice President, U.S. Thought Leadership